Limits...
Genetic association between PER3 genetic polymorphisms and cancer susceptibility: a meta-analysis.

Geng P, Ou J, Li J, Wang N, Xie G, Sa R, Liu C, Xiang L, Liang H - Medicine (Baltimore) (2015)

Bottom Line: We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat.For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67).No substantial heterogeneity was revealed in this analysis.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.

ABSTRACT
The genes along the circadian pathways control and modulate circadian rhythms essential for the maintenance of physiological homeostasis through self-sustained transcription-translation feedback loops. PER3 (period 3) is a circadian pathway gene and its variants (rs1012477, 4/5-repeat) have frequently been associated with human cancer. The mixed findings, however, make the role of the 2 variants in cancer susceptibility elusive. We aimed in this article to clarify the association of PER3 variants with cancer. We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat. Based on the genotype and allele frequency, we chose the fixed-effects model to estimate risk of cancer. Overall analysis did not suggest a global role of rs1012477 in cancer susceptibility. For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67). No substantial heterogeneity was revealed in this analysis. Our meta-analysis provides no evidence supporting a global association of PER3 genetic variants with the incidence of cancer.

Show MeSH

Related in: MedlinePlus

A Flow chart summarizing the study selection process. PER3 =  period 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554033&req=5

Figure 1: A Flow chart summarizing the study selection process. PER3 =  period 3.

Mentions: Figure 1 summarizes the reasons of excluding/including studies. We first evaluated the title and abstract of all 621 retrieved records, and discarded 572 expression- or survival-based and nonhuman studies. We were left with 49 records and then read through the texts. A total of 41 papers were further excluded, because they addressed circadian genes rather than PER3, investigated PER3 variants without any genetic data, or published as review articles. After excluding all ineligible records, we were finally left with 8 retrospective studies.15–20,22,23


Genetic association between PER3 genetic polymorphisms and cancer susceptibility: a meta-analysis.

Geng P, Ou J, Li J, Wang N, Xie G, Sa R, Liu C, Xiang L, Liang H - Medicine (Baltimore) (2015)

A Flow chart summarizing the study selection process. PER3 =  period 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554033&req=5

Figure 1: A Flow chart summarizing the study selection process. PER3 =  period 3.
Mentions: Figure 1 summarizes the reasons of excluding/including studies. We first evaluated the title and abstract of all 621 retrieved records, and discarded 572 expression- or survival-based and nonhuman studies. We were left with 49 records and then read through the texts. A total of 41 papers were further excluded, because they addressed circadian genes rather than PER3, investigated PER3 variants without any genetic data, or published as review articles. After excluding all ineligible records, we were finally left with 8 retrospective studies.15–20,22,23

Bottom Line: We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat.For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67).No substantial heterogeneity was revealed in this analysis.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.

ABSTRACT
The genes along the circadian pathways control and modulate circadian rhythms essential for the maintenance of physiological homeostasis through self-sustained transcription-translation feedback loops. PER3 (period 3) is a circadian pathway gene and its variants (rs1012477, 4/5-repeat) have frequently been associated with human cancer. The mixed findings, however, make the role of the 2 variants in cancer susceptibility elusive. We aimed in this article to clarify the association of PER3 variants with cancer. We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat. Based on the genotype and allele frequency, we chose the fixed-effects model to estimate risk of cancer. Overall analysis did not suggest a global role of rs1012477 in cancer susceptibility. For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67). No substantial heterogeneity was revealed in this analysis. Our meta-analysis provides no evidence supporting a global association of PER3 genetic variants with the incidence of cancer.

Show MeSH
Related in: MedlinePlus